|
AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
|
31 January 2023 |
|
FDA approves RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for adults with moderate to severe rheumatoid arthritis
|
06 June 2022 |
|
Amgen and Plexium announce multi-year, drug discovery collaboration to identify novel targeted protein degradation therapies
|
03 February 2022 |
|
Amgen and Arrakis Therapeutics announce multi-target collaboration to identify novel RNA degrader small molecule therapeutics
|
11 January 2022 |
|
Tezepelumab granted Priority Review by U.S. FDA
|
08 July 2021 |
|
Amgen successfully completes acquisition of Five Prime Therapeutics
|
16 April 2021 |
|
Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies
|
17 September 2020 |
|
Amgen and Adaptive Biotechnologies announce strategic partnership to develop a therapeutic to prevent or treat COVID-19
|
02 April 2020 |
|
Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts
|
26 March 2020 |
|
Amgen, Cytokinetics and Servier announce continuation of GALACTIC-HF following planned interim analysis
|
26 February 2020 |
|
Free "LabXchange" science education accelerator launched by Amgen Foundation and Harvard's Faculty of Arts and Sciences
|
22 January 2020 |
|
Amgen announces global diagnostic collaborations
|
13 January 2020 |
|
Amgen commences strategic collaboration with BeiGene to expand oncology presence in China
|
06 January 2020 |
|
Amgen and Allergan submit Biologics License Application for ABP 798, biosimilar candidate to Rituxan® (rituximab)
|
19 December 2019 |
|
Amgen completes acquisition of Otezla® (apremilast)
|
21 November 2019 |
|
Amgen and the Duke Clinical Research Institute announce initiation of first large-scale registry to evaluate real-world lipid management and the effectiveness of PCSK9 inhibitors
|
18 November 2019 |
|
Amgen recommends rejection of 'mini-tender' offer from TRC Capital Corporation
|
23 October 2019 |
|
Nplate® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia
|
21 October 2019 |
|
Amgen announces positive results from two Phase 3 BLINCYTO® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia
|
25 September 2019 |
|
Amgen to acquire Otezla® for $13.4 billion in cash
|
26 August 2019 |